E3 PreliminaryPreliminaryPEM not requiredReview-NarrativePeer-reviewedReviewed
Standard · 3 min
[Chronic fatigue syndrome and neurotransmitters].
Miwa, Soichi, Takikawa, Osamu · Nihon rinsho. Japanese journal of clinical medicine · 2007
Quick Summary
This review examines how chemical messengers in the brain called neurotransmitters may be disrupted in ME/CFS. The researchers found that ME/CFS patients may have problems with serotonin and glutamate signaling, possibly triggered by viral infections or genetic differences. These imbalances could help explain why ME/CFS causes such persistent exhaustion.
Why It Matters
This work is important because it provides a biological framework for understanding ME/CFS beyond just measuring fatigue symptoms. By identifying potential neurotransmitter mechanisms, the research opens pathways for developing targeted treatments and biomarkers that could validate ME/CFS as a physiological illness.
Observed Findings
Increased serotonin transporter expression has been associated with reduced serotonin neurotransmission in CFS
Viral infection and interferon-alpha production may trigger abnormal serotonin transporter regulation
Glutamate neurotransmission appears attenuated in CFS patients
Abnormal acylcarnitine metabolism may contribute to neurotransmitter system dysfunction
Autoantibodies targeting neurotransmitter receptors have been detected in some CFS patients
Inferred Conclusions
ME/CFS likely involves dysfunction in multiple neurotransmitter systems rather than a single mechanism
Viral infections may trigger persistent neurochemical imbalances through interferon and immune dysregulation
Both genetic factors (serotonin transporter gene polymorphisms) and acquired factors (metabolic abnormalities, autoantibodies) may converge on similar neurotransmitter deficits
Neurotransmitter dysfunction represents a tractable biological target for future therapeutic intervention
Remaining Questions
Which neurotransmitter abnormality is primary versus secondary in ME/CFS pathogenesis?
What This Study Does Not Prove
This review does not prove that neurotransmitter dysfunction causes ME/CFS or establish which mechanism is primary. It does not provide new experimental evidence demonstrating these mechanisms in ME/CFS patients, nor does it clarify the relative contribution of each proposed pathway (viral, genetic, metabolic, or autoimmune) to neurotransmitter abnormalities.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.